BCM
TCRR

BlueCrest Capital Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

BlueCrest Capital Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-26,255
Closed -$458K – 1131
2019
Q1 		$458K Buy
+26,255
New +$466K 0.02% 525

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlueCrest Capital Management's TCRR Position: Q2 2019 in Review

BlueCrest Capital Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2019, closing a stake of 26,255 shares — an estimated $458K sold.

BlueCrest Capital Management first reported a position in TCRR in Q1 2019 and held it in 1 quarter. The position peaked at $458K in Q1 2019. 33 funds tracked by Wall St. Rank hold TCRR as of Q2 2019.

  • BlueCrest Capital Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 26,255 TCR2 Therapeutics Inc. Common Stock shares in Q2 2019, an estimated $458K.
  • BlueCrest Capital Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's TCR2 Therapeutics Inc. Common Stock position peaked at $458K in Q1 2019.
  • 33 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.